Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $2.41 billion. The enterprise value is $2.14 billion.
| Market Cap | 2.41B |
| Enterprise Value | 2.14B |
Important Dates
The last earnings date was Wednesday, August 6, 2025, after market close.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 78.67 million shares outstanding. The number of shares has increased by 7.42% in one year.
| Current Share Class | 78.67M |
| Shares Outstanding | 78.67M |
| Shares Change (YoY) | +7.42% |
| Shares Change (QoQ) | -2.08% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 112.36% |
| Float | 78.23M |
Valuation Ratios
The trailing PE ratio is 91.40 and the forward PE ratio is 23.60. Veracyte's PEG ratio is 0.47.
| PE Ratio | 91.40 |
| Forward PE | 23.60 |
| PS Ratio | 4.98 |
| Forward PS | 4.58 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 6.86 |
| P/FCF Ratio | 28.75 |
| P/OCF Ratio | 25.83 |
| PEG Ratio | 0.47 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.61, with an EV/FCF ratio of 25.53.
| EV / Earnings | 81.40 |
| EV / Sales | 4.47 |
| EV / EBITDA | 33.61 |
| EV / EBIT | 52.54 |
| EV / FCF | 25.53 |
Financial Position
The company has a current ratio of 5.43, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.43 |
| Quick Ratio | 4.86 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.67 |
| Debt / FCF | 0.60 |
| Interest Coverage | 20,398.50 |
Financial Efficiency
Return on equity (ROE) is 2.24% and return on invested capital (ROIC) is 2.10%.
| Return on Equity (ROE) | 2.24% |
| Return on Assets (ROA) | 1.98% |
| Return on Invested Capital (ROIC) | 2.10% |
| Return on Capital Employed (ROCE) | 3.22% |
| Revenue Per Employee | $581,467 |
| Profits Per Employee | $31,960 |
| Employee Count | 824 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 6.37 |
Taxes
In the past 12 months, Veracyte has paid $2.63 million in taxes.
| Income Tax | 2.63M |
| Effective Tax Rate | 9.09% |
Stock Price Statistics
The stock price has increased by +2.54% in the last 52 weeks. The beta is 1.97, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | +2.54% |
| 50-Day Moving Average | 26.21 |
| 200-Day Moving Average | 33.68 |
| Relative Strength Index (RSI) | 70.46 |
| Average Volume (20 Days) | 2,453,257 |
Short Selling Information
The latest short interest is 9.08 million, so 11.54% of the outstanding shares have been sold short.
| Short Interest | 9.08M |
| Short Previous Month | 6.11M |
| Short % of Shares Out | 11.54% |
| Short % of Float | 11.60% |
| Short Ratio (days to cover) | 4.89 |
Income Statement
In the last 12 months, Veracyte had revenue of $479.13 million and earned $26.34 million in profits. Earnings per share was $0.34.
| Revenue | 479.13M |
| Gross Profit | 338.02M |
| Operating Income | 40.80M |
| Pretax Income | -54.79M |
| Net Income | 26.34M |
| EBITDA | 63.78M |
| EBIT | 40.80M |
| Earnings Per Share (EPS) | $0.34 |
Balance Sheet
The company has $320.72 million in cash and $50.65 million in debt, giving a net cash position of $270.07 million or $3.43 per share.
| Cash & Cash Equivalents | 320.72M |
| Total Debt | 50.65M |
| Net Cash | 270.07M |
| Net Cash Per Share | $3.43 |
| Equity (Book Value) | 1.22B |
| Book Value Per Share | 15.54 |
| Working Capital | 338.25M |
Cash Flow
In the last 12 months, operating cash flow was $93.45 million and capital expenditures -$9.49 million, giving a free cash flow of $83.97 million.
| Operating Cash Flow | 93.45M |
| Capital Expenditures | -9.49M |
| Free Cash Flow | 83.97M |
| FCF Per Share | $1.07 |
Margins
Gross margin is 70.55%, with operating and profit margins of 8.51% and 5.50%.
| Gross Margin | 70.55% |
| Operating Margin | 8.51% |
| Pretax Margin | 6.05% |
| Profit Margin | 5.50% |
| EBITDA Margin | 13.31% |
| EBIT Margin | 8.51% |
| FCF Margin | 17.52% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.42% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.09% |
| FCF Yield | 3.48% |
Analyst Forecast
The average price target for Veracyte is $39.89, which is 30.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.89 |
| Price Target Difference | 30.02% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 6.58% |
| EPS Growth Forecast (5Y) | 46.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 12.85 and a Piotroski F-Score of 7.
| Altman Z-Score | 12.85 |
| Piotroski F-Score | 7 |